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Background: The purpose of the study was to evaluate the benefit of adjuvant chemotherapy (AC) versus surgery
alone in patients with muscle-invasive bladder cancer (MIBC).
Patients and methods: One hundred and ninety-four patients with pT2G3, pT3–4, N0–2 transitional cell bladder
carcinoma were randomly allocated to control (92 patients) or to four courses of AC (102 patients). These latter
patients were further randomly assigned to receive gemcitabine 1000 mg/m2 days 1, 8 and 15 and cisplatin 70 mg/m2
day 2 or gemcitabine as above plus cisplatin 70 mg/m2 day 15, every 28 days.
Results: At a median follow-up of 35 months, the 5-year overall survival (OS) was 48.5%, with no difference between
the two arms [P = 0.24, hazard ratio (HR) 1.29, 95% confidence interval (CI) 0.84–1.99]. Mortality hazard was
significantly correlated with Nodes (N) and Tumor (T) stage. The control and AC arms had comparable disease-free
survival (42.3% and 37.2%, respectively; P = 0.70, HR 1.08, 95% CI 0.73–1.59). Only 62% of patients received
the planned cycles. A significant higher incidence of thrombocytopenia was observed in patients receiving cisplatin
on day 2 (P = 0.006). A similar global quality of life was observed in the two arms.
Conclusion: The study was underpowered to demonstrate that AC with cisplatin and gemcitabine improves OS and
disease-free survival in patients with MIBC.
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introduction
Bladder cancer represents the fifth most common cancer in
Europe [1], and 60% of patients with bladder cancer will
develop a muscle-invasive disease.
Until recently, radical cystectomy was considered the gold
standard of the treatment of muscle-invasive bladder cancer
(MIBC), and although new surgical techniques [2, 3] reduced
the morbidity and mortality related to this procedure, the 5-year
survival rates for all stages still range from 48% to 66% [4, 5].
Recently, two meta-analyses showed a significant overall
survival (OS) benefit in favor of neoadjuvant cisplatin-based
chemotherapy, thus making it the new standard of care for
these patients [6, 7]. In respect to neoadjuvant chemotherapy,
adjuvant chemotherapy (AC) has several putative advantages,
namely, it is administered to patients properly selected on the
basis of factors predicting for relapse and it does not imply any
delay of definitive treatment.
Several randomized trials have been done to investigate the
use of AC in MIBC [8–14]. Almost all these studies provide
insufficient evidence to support the routine use of AC, due to
small sample sizes, early stopping of patient entry, confusing
analyses and terminology and the reporting of questionable
conclusions [15, 16]. Two meta-analyses [17, 18] provided
statistically significant evidence in favor of AC relative to OS
and disease-free survival. However, both meta-analyses’ results
should be carefully evaluated before considering AC as
a current standard for these patients because of both the small
number of trials and the patients included and should be rather
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regarded as a first step toward generating new hypotheses to be
tested in larger randomized trials [19, 20].
In advanced bladder cancer, the combination of cisplatin (C;
day 2) and gemcitabine (G; days 1, 8, 15) has been
demonstrated to be as effective as M-VAC (combination
chemotherapy with methotrexate, vinblastine, doxorubicin and
cisplatin) but with less myelotoxicity [21]. On the other hand,
the schedule of cisplatin (day 15) plus gemcitabine, which has
proven to further reduce the bone marrow toxicity in non-
small-cell lung cancer patients [22, 23], has not been tested in
adjuvant bladder cancer.
This phase III, Italian, multicenter randomized clinical trial
aimed to demonstrate the efficacy of chemotherapy
administered immediately after radical cystectomy versus the
same chemotherapy administered at the time of disease
recurrence.
patients and methods
patients
Patients with histologically proven transitional cell carcinoma of the
bladder pT2 G3 (N0–2), pT3–4 (N0–2) any G or pN1–2, any Tumor (T),
any G were considered eligible. A radical cystectomy with no residual
disease and a minimum of 10 lymph nodes dissection was required.
Randomization was required within 10 weeks after surgery. Neither prior
neoadjuvant chemotherapy nor radiotherapy was allowed, while no
restrictions were applied to prior endoluminal therapy. Eligible patients
were also required to have an Eastern Cooperative Oncology Group
performance status (PS) of two or less, age £ 75 years, adequate bone
marrow reserve and a good renal (creatinine level £ 1.25 lmol/l, measured
creatinine clearance ‡ 60 ml/min) and liver function. The trial was
conducted according to the guidelines of the Helsinki Declaration and
approved by all institutional ethics committees. All patients were required
to sign a written informed consent before randomization.
study design and allocated treatments
After cystectomy, patients were randomly assigned (1 : 1) to observation
and treatment on relapse (arm A) or AC (arm B). Before randomization,
two stratification factors were considered: nodal involvement (N0 versus
N1–2) and investigator center. Treatment allocation was established by the
two coordinating centers using computer-generated random lists.
Patients in the AC arm were further randomly assigned (1 : 1) to receive
two different schedules of the same regimen (arm B2 and arm B15). Patients
on the B2 arm received gemcitabine 1000 mg/m2 i.v. over 30 min, days 1, 8
and 15 plus cisplatin 70 mg/m2 i.v. on day 2; patients on the B15 arm received
the same gemcitabine schedule as for B2 arm, but cisplatin at the same dose
was administered on day 15. On both arms, cycles were repeated every 28
days for a total of four cycles. Patients randomly assigned to observation arm
were scheduled to be treated at first evidence of recurrence with one of the
two cisplatin–gemcitabine regimens, at investigator’s discretion.
Hematologic and non-hematologic toxicities were graded according to
the World Health Organization (WHO) grading system [24].
Both drugs were omitted for grade 4 toxicity, whereas a 50% dose
reduction was planned for grade 3 hematological and non-hematological side-
effects. The dose of cisplatin was splitted in 2 days if measured creatinine
clearance was 50–59 ml/min and omitted for creatinine clearance <49 ml/min.
trial end points and evaluations
The primary end point of the study was the comparison of the OS, defined
as the time from randomization to death for any cause, between control
and AC arm. Secondary aims were disease-free survival, defined as the time
from randomization to the earliest occurrence of recurrence or death from
any cause, toxicity of the two GC schedules, and quality of life (QoL).
All patients were clinically staged before randomization by computed
tomography (CT) and bone scan. All patients had clinical and laboratory
evaluation at baseline and during treatment. In the control arm and at the
end of chemotherapy in the AC arms, patients were examined at 3-month
intervals for the first 2 years, then every 6 months for further 3 years and
then yearly thereafter. CT scan was carried out every 6 months for the first 3
years and on an annual basis thereafter. QoL tests were compiled at the
study entry; at 2, 3 and 4 months and then at 6 and 12 months. Relapse was
defined as the detection of at least one lesion that could not be identified as
an independent second malignancy.
sample size and statistical analysis
Sample size was determined according to the survival data reported in the
literature indicating that the annual risk of death for patients with MIBC
following radical cystectomy was 35% [8–11], which means a 2-year
probability of survival of 50%. The hypothesis was that AC would be able to
improve 2-year OS of 10%: assuming an a error of 0.05 and a power of
80%, it was calculated that 610 patients (305 for each arm) should be
accrued in 3 years and followed for further 2 years. All analyses were carried
out according to the intent-to-treat principle. In order to evaluate the
hypothesis of a relative difference of 30% in the incidence of
thrombocytopenia between arm B2 and arm B15 (relative risk = 0.70), it
was estimated that overall 350 patients would be required.
Survival curves were estimated by the Kaplan–Meier method and
compared using the log-rank test. Data were reported as 5-year percentages
and their standard errors. Additional analyses were done by the Cox
proportional hazards model with the aim to adjust estimations for multiple
baseline characteristics.
Comparisons of proportions between the two groups were carried out
using a two-sided v2 test or a two-sided Fisher’s exact test, as
appropriate.
results
Because of the low accrual rate, the trial was prematurely closed
and the final analysis was carried out in July 2009. From
September 2001 to July 2007, 194 patients from 45 Italian
centers (see Appendix 1) were entered on to the trial, 92 in the
control arm and 102 in the AC arm. Eleven patients, six in arm
A and five in arm B, were lost after randomization and were not
considered assessable for final analysis. Of the 97 assessable
patients in the chemotherapy arm, 8 patients refused to start
chemotherapy and were not included in the toxicity analysis. Of
the remaining 89, 43 patients were randomly assigned to receive
cisplatin on day 2 (arm B2) and 46 to receive cisplatin on day
15 (arm B15).
Patient characteristics were balanced between the two arms
except for pN2, which were more in the CT group, but the
difference was not statistically significant (Table 1). A poorly
differentiated tumor grade was predominant in both arms and
almost half of the patients had positive regional lymph nodes.
Median time to therapy in the adjuvant arm was 8 weeks,
ranging from 4 to 12 weeks.
overall survival
At a median follow-up of 35 months (interquartile range 15–57),
84 patients had died (arm A, N = 38; arm B, N = 46). Tumor was
the cause of death in 34 patients in the control arm and in 39
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patients in the chemotherapy arm. Eleven patients died in
absence of proven tumor progression (five in the control arm and
six in the AC arm). The 5-year OS of the whole series was 48.5%
(standard error 4.2%), slightly higher than expected, probably
due to the consistent percentage of node-negative patients
included, with no significant difference between the two arms
(P = 0.24): 53.7% in the control group and 43.4% in the AC arm.
No difference in OS according to GC schedule was evident in the
AC arm: 46.6% of patients assigned to the B2 schedule were
alive at 5 years compared with 39.9% of those assigned to the
B15 schedule (P = 0.88). Survival curves are shown in Figure 1.
In patients with lymph node-negative disease, 5-year OS rates
were 73.2% in the control arm and 64.5% in the AC arm (P =
0.65); whereas in patients with lymph node involvement, OS
rates were 27.6% and 25.8% in the control and AC groups,
respectively (P = 0.71).
The hazard ratio (HR) for mortality from any cause
according to treatment (chemotherapy versus control) also
failed to reveal any difference in OS between the two arms [HR
1.29; 95% confidence interval (CI) 0.84–1.99; P = 0.24].
Mortality analysis confirmed that, independently of treatment
arm, mortality hazard was significantly correlated with nodal
status (pN1 versus pN0: HR 2.42; 95% CI 1.38–4.26; pN2
versus pN0: HR 4.33; 95% CI 2.60–7.20) and T stage (pT3
versus pT1–2: HR 2.01; 95% CI 1.14–3.56; pT4 versus pT1–2:
HR 2.57; 95% CI 1.34–4.92). These results were confirmed also
by multivariate analysis (data not shown).
disease-free survival
Overall, tumor relapse occurred in 83 patients, 40 in arm A and
43 in arm B. The first site of relapse were the pelvis in 11
patients (6 in arm A and 5 in arm B); the bones in 15 patients
(7 in arm A and 8 in arm B); the lungs in 10 patients (5 in arm
A and 5 in arm B) and the lymph nodes in 12 patients (8 in arm
A and 4 in arm B). Twenty-seven patients relapsed at more than
one site (11 in arm A and 16 in arm B). Secondary primary
tumors were reported in nine patients.
The 5-year disease-free survival of the whole cohort on study
was 39.5% (standard error 3.9%). The control and AC arms
were almost comparable relative to disease-free survival: 42.3%,
arm A and 37.2%, arm B (P = 0.70, HR 1.08; 95% CI 0.73–
1.59). Disease-free survival curves are shown in Figure 2.
In the subgroup analysis according to nodal status, the 5-year
disease-free survival of the node-negative patients was 59.5% in
the control arm and 57.6% in the AC arm (P = 0.97). In node-
positive patients, 5-year disease-free survival was 19.4% in the
control group and 18.9% in the AC group (P = 0.80).
Treatments received at relapse are listed on Table 2.
toxicity
Patients in the AC arm received in total 297 cycles, 135 in arm
B2 and 162 in arm B15. Overall, 92% of patients completed
the first cycle, 78% two cycles, 74% three cycles and only 62%
of patients received the planned four cycles, mainly due to
treatment-related toxic effects. In the B2 arm, 67% required
dose adjustment and 39% patients required an early stop
treatment. In the B15 arm, a dose reduction and an early stop
treatment was required for 72% and 26% patients,
respectively. All the WHO hematologic and non-hematologic
toxic effects observed in B2 and B15 arms are listed in Table 3.
A statistically significant higher incidence of grade 3/4
thrombocytopenia was observed in B2 arm as compared with
B15 arm (25.6% versus 4.3%, P = 0.006). On the contrary,
patients in B15 arm experienced more grade 3/4 leukopenia
(15.2% versus 9.3%) and neutropenia (34.8% versus 21%),
not reaching statistical significance. The incidence of grade 3
and 4 nausea and vomiting was higher in B2 arm (9.4% versus
Table 1. Patient characteristics
Control (N = 86),
n (%)
AC (N = 97),
n (%)
Median age (range), years 63 (36–75) 64 (38–75)
Sex
Male 75 (87.2) 90 (92.8)
Female 11 (12.8) 7 (7.2)
PS (ECOG)
0 61 (70.9) 79 (81.4)
1–2 21 (24.4) 16 (16.5)
Missing 4 (4.7) 2 (2.1)
Histology
Transitional cell carcinoma 85 (98.8) 95 (97.9)
Other 1 (1.2) 2 (2.1)
T grade
G2 4 (4.7) 3 (3.1)
G3 80 (93.0) 90 (92.8)
Gx or missing 2 (2.3) 4 (4.1)
T stage
pT1 1 (1.1) 3 (3.1)
pT2 19 (22.1) 29 (29.9)
pT3 49 (57.0) 46 (47.4)
pT4 17 (19.8) 19 (19.6)
Lymph nodal status
pN0 49 (57.0) 47 (48.5)
pN1 19 (22.1) 20 (20.6)
pN2 18 (20.9) 30 (30.9)
AC, adjuvant chemotherapy; PS, performance status; ECOG, Eastern
Cooperative Oncology Group; T, tumor; pT, pathological Tumor; pN,
pathological Nodes.
Figure 1. Kaplan–Meier curves for overall survival in patients who
underwent chemotherapy or observation. AC, adjuvant chemotherapy;
HR, hazard ratio; CI, confidence interval.
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2.2%, P = 0.31). No drug toxicity-related death was observed
in either arm.
Global QoL was similar for patients assigned both to control
and to AC arm. In this latter group, there was a slight
worsening of the general QoL during the last 2 months of
chemotherapy, with a subsequent improvement during follow-
up so returning comparable with the control group.
discussion
The present study is an Italian, multicenter, randomized phase
III trial comparing immediate AC with cisplatin and
gemcitabine versus the same chemotherapy at relapse in
patients with MIBC who underwent radical cystectomy. Our
study was underpowered to demonstrate that AC improves OS
and disease-free survival in these patients.
Despite being limited by an accrual much slower than expected
and by the small number of patients recruited, much lower than
that originally planned, this is the largest phase III trial reported
so far exploring the role of AC in patients with MIBC.
The choice of the cisplatin–gemcitabine regimen was made
on the basis of the results of a large phase III trial in the
metastatic setting, comparing this regimen versus M-VAC,
showing comparable responses but a lower toxicity of the GC
regimen [21, 25]. In fact, in our study, both hematological and
non-hematological toxicities were acceptable with a low
incidence of grade 3–4 side-effects, with the exception of
thrombocytopenia, which occurred significantly more
frequently in the B2 arm. These data confirm the results
obtained in two prior studies [22, 23].
In spite of the quite acceptable incidence and severity of
chemoinduced toxic effects, our trial confirmed that the
compliance of patients to chemotherapy after radical
cystectomy was poor. Only 62% of patients could complete
chemotherapy as planned, and more than half of the patients
required a dose reduction. These data confirm that the
compliance of patients to chemotherapy after radical
cystectomy decreases rapidly with a lower tolerance to drugs.
The low compliance to AC was previously reported in other
studies also [8, 9] and can partly explain the negative results of
most previous published randomized trials [10–13]. The
putative difficulties in delivering AC to bladder cancer patients
should be taken into adequate account in treatment planning.
Despite this data compliance, the QoL of patients who
received AC seems to be similar to the one observed in patients
treated with surgery alone. This could be probably due to the
high number of dose reductions and/or early termination of
treatment in that arm.
As shown in Table 2, only 62% of patients were treated for
metastatic disease, and 75% of them received the planned
gemcitabine–cisplatin regimen. Several patients were not
Figure 2. Kaplan–Meier curves for disease-free survival in patients who
underwent chemotherapy or observation. AC, adjuvant chemotherapy;
HR, hazard ratio; CI, confidence interval.
Table 2. Treatment of relapsed patients
Control (total
PD = 40)
AC (total
PD = 43)
CDDP/GEM (B2 schedule) 9 –
CDDP/GEM (B15 schedule) 4 –
CDDP/GEM (other schedules) 5 3
Other chemotherapiesa 5 18
Surgery 1 3
RT 2 2
Best supportive care 5 11
Missing 9 6
aM-VAC and regimens containing carboplatin and/or paclitaxel.
AC, adjuvant chemotherapy; CDDP, cisplatin; GEM, gemcitabine; B2,
cisplatin administered on day 2; B15, cisplatin administered on day 15; RT,
radiotherapy; M-VAC, combination chemotherapy with methotrexate,
vinblastine, doxorubicin and cisplatin; PD, progressive disease.
Table 3. Summary of treatment-related toxic effects
CDDP/GEM
(B2; N = 43),
%
CDDP/GEM
(B15; N = 46),
%
All 3/4 All 3/4
Leukopenia 65 9 66 15
Neutropenia 68 21 70 35
Anemia 63 5 55 6
Thrombocytopenia 49 26 45 4
Fever 39 – 28 2
Nausea–vomiting 48 9 54 2
Cefalea 7 – 4 –
Diarrhea 19 2 17 –
Stomatitis–mucositis 21 – 11 4
Hypertransaminasemia – – 4 2
Hypercreatininemia 14 – 15 –
Decrease creatinine
clearance
14 2 9 –
Proteinuria 14 – 4 –
Alopecia 28 2 23 2
Infection 21 5 11 –
Asthenia 65 5 46 2
CDDP, cisplatin; GEM, gemcitabine; B2, cisplatin administered on day 2;
B15, cisplatin administered on day 15.
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suitable to receive a first-line chemotherapy or a cisplatin-
containing regimen. This result confirms that metastatic
bladder cancer can occur in a very aggressive way that does not
always allow to submit patients to the same chemotherapy
regimen planned in the adjuvant setting.
Seven randomized trials have compared AC with observation
after cystectomy [8–14]. All these trials used combination
platinum-based chemotherapy except for one that tested the
value of cisplatinum monotherapy [10]. Three trials [8, 9, 14]
showed an advantage in OS in favor of the patients assigned to
adjuvant therapy and the other four studies were negative
[10–13]. The lack of advantage from AC observed in these trials
was probably due to the small sample size and in some studies
due to the suboptimal treatment option. These studies included
<100 patients, except for the Paz-Ares trial, and were all
stopped prematurely on the basis of an interim analysis,
favoring the chemotherapy group.
Beyond their small size, long recruitment period, early
stopping on the basis of interim analysis and inadequacy of the
chemotherapy employed, most of these studies are also biased
by the lack of standardization of treatment on progression. This
aspect might be crucial relative to OS estimation. In fact, on
one hand, it is well known that patients with metastatic disease
can benefit from frontline chemotherapy [26, 27]. On the other
hand, no chemotherapy regimen can be regarded yet as the
standard to manage the patients who fail adjuvant cisplatin-
based chemotherapy. Standardization of treatment on relapse is
one of the points of strength of our study, though our findings
confirm that only a limited proportion of the recurring patients
can actually be managed by full-dose chemotherapy regimens,
mainly due to a rapid decline in PS.
In order to better clarify the impact of AC for radically
removed bladder cancer, two meta-analyses were carried out,
both of them providing a moderate but statistically significant
survival benefit in favor of the treated patients, regardless of the
chemotherapy regimen employed [17, 18, 28]. In particular, in
the individual patient data meta-analysis (6 gathered trials, 491
collected patients), a 25% significant reduction in the risk of
death (P = 0.019) in favor of the AC was found, with an
absolute benefit of 9% at 3 years [17]. Actually, the clinical
heterogeneity (i.e. surgical technique, the chemotherapy
regimen and drugs, the patient selection with particular regard
to the node status at surgery, the trial design) and the overall
sample size, which was certainly underpowered to detect that
difference (900 events would have been required, with 80%
power and 5% significance), did not suggest any definitive
recommendation on the use of AC.
Our study enrolled 190 patients, an accrual that was larger
than in other intergroup trials, and confirmed the feasibility of
the adjuvant approach in patients with MIBC. Unfortunately, the
number of patients who entered the study remains the major
limit of the present trial, considering that the original plan was to
recruit 610 patients. Thus, no meaningful conclusion can be
extrapolated from a study with any adequate power. In fact, with
less than one-third of the planned patients, our trial has a high
chance to be falsely negative. However, our study might give an
important contribution to the meta-analysis.
A phase III trial comparing four cycles of adjuvant
paclitaxel–gemcitabine–cisplatin regimen with observation was
recently presented [14]. The Spanish trial randomly allocated
68 patients to the chemotherapy arm and 74 patients to the
observation arm. At median follow-up of 29.8 months, Paz-
Ares reported a significant advantage for AC in terms of OS (P
< 0.0009) and progression-free survival (P < 0.0001).
Given the opposite results coming from our study and the
Spanish trial, the update of the literature-based meta-analysis
previously carried out does confirm the benefit in favor of AC
(8 trials, 827 patients, relative risk reduction of 14%, P =
0.034, heterogeneity P = 0.27, absolute benefit 4.9%,
corresponding to 20–21 number of patients needed to treat
for one to benefit), with no significant interaction (P = 0.40)
according to the number of administered drugs (data not
shown).
Moreover, it further supports the conclusion that there is
insufficient evidence to reliably base any treatment decision.
This has to be properly taken into account not only for
decision making in the everyday practice but also in trial
designing. Due to the present uncertainness relative to the
more appropriate way to manage these patients, there is still
an urgent need for further research into the use of AC in
MIBC. It is necessary that future studies have adequate
statistical power or learn more about the biology of this
tumor. In fact, few biologic tumor characteristics, such as
ERCC-1 and BRCA1 expression level, are known to be
predictive of chemosensitivity in bladder cancer [29] and are
factors to consider, in order to develop more effective
strategies with smaller number of patients.
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appendix 1
Members of the Study Group, which selects, enrolls and/or
treats patients, were (number of patients included) as follows:
Cantiani R., Istituto Tumori Regina Elena, Roma (56); Aglietta
M., IRCC Candiolo, Torino (17); Bertetto O., Ospedale San
Giovanni, Torino (9); Cetto G. L., Ospedale Civile Maggiore
Borgo Trento, Verona (7); Orlandini P., Azienda Ospdaliera
Pisana, Pisa (7); Ferrazzi E., Ospedale Civile, Rovigo (6); Nardi
M., Ospedali Riuniti, Reggio Calabria (5); Ospedale Casa
Sollievo della Sofferenza, San Giovanni Rotondo (Bari) (5);
Manzione L., Ospedale San Carlo, Potenza (5); Adamo V.,
Policlinico Universitario G. Martino, Messina (4); Porcile G.,
Ospedale San Lazzaro, Alba (CN) (4); Lentini M., Ospedale San
Camillo-Forlanini, Roma (3); Breda E., Ospedale
Fatebenefratelli, Roma (3); Gamucci T., Ospedale S.S. Trinita`,
Sora (3); Tummarello D., Ospedali Riuniti, Ancona (3);
Dogliotti L., Ospedale San Luigi, Orbassano (TO) (3); Tumolo
S., Ospedale Civile S.M. degli Angeli, Pordenone (3); Motta M.,
Ospedale V. Emanuele, Catania (2); Lo Russo V., Istituto
Oncologico, Bari (2); De Grande G., Azienda Ospedaliera
Umberto I, Siracusa (2); Sacco C., Ospedale Santa Maria della
Misericordia, Udine (2); Gaion F., Ospedale Camposanpiero,
Citta della Pieve (PD) (2); Lavarello A., Ospedale Civile, Sestri
Levante (GE) (2); Nuzzo A., Ospedale Civile Renzetti, Lanciano
(CH) (2); Clerico M., Ospedale Infermi, Biella (2); Aragona C.,
Ospedale Papardo, Messina (1); Gernone A., Policlinico di Bari,
Ospedale Giovanni XXIII, Bari (1); Morelli F., Olivito V.,
Mater Domini, Catanzaro (1); Cupini, Ospedale Umberto I,
Frosinone (1); Mattioli R., Ospedale S. Croce, Fano (1);
Aiello Istituto San Luigi, Catania (1); Marra A., Ospedale
Cardarelli, Napoli (1); Antimi M., Ospedale Sant’Eugenio,
Roma (1); Silingardi V., Policlinico Universitario, Modena (1);
Labianca R., Ospedali Riuniti, Bergamo (1); Martoni A.,
Ospedale S. Orsola, Bologna (1); Bortolussi V., Ospedale di
Portogruaro, Portogruaro (VE) (1); Luoni M.,
Ospedale Civile Legnano, Legnano (MI) (1); Rosabian A.,
Ospedale Civile Boldrini, Thiene (VC) (1); Di Vito F.,
Ospedale Civile, Aosta (1); Catalano G., Ospedale San
Salvatore, Pesaro (1); Gebbia N., Policlinico Universitario,
Palermo (1).
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